These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

288 related items for PubMed ID: 11376111

  • 21. Ligand- and coactivator-mediated transactivation function (AF2) of the androgen receptor ligand-binding domain is inhibited by the cognate hinge region.
    Wang Q, Lu J, Yong EL.
    J Biol Chem; 2001 Mar 09; 276(10):7493-9. PubMed ID: 11102454
    [Abstract] [Full Text] [Related]

  • 22. Complete androgen insensitivity syndrome caused by a novel mutation in the ligand-binding domain of the androgen receptor: functional characterization.
    Rosa S, Biason-Lauber A, Mongan NP, Navratil F, Schoenle EJ.
    J Clin Endocrinol Metab; 2002 Sep 09; 87(9):4378-82. PubMed ID: 12213902
    [Abstract] [Full Text] [Related]

  • 23. Impaired nuclear translocation, nuclear matrix targeting, and intranuclear mobility of mutant androgen receptors carrying amino acid substitutions in the deoxyribonucleic acid-binding domain derived from androgen insensitivity syndrome patients.
    Kawate H, Wu Y, Ohnaka K, Tao RH, Nakamura K, Okabe T, Yanase T, Nawata H, Takayanagi R.
    J Clin Endocrinol Metab; 2005 Nov 09; 90(11):6162-9. PubMed ID: 16118342
    [Abstract] [Full Text] [Related]

  • 24. Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor2).
    Berrevoets CA, Doesburg P, Steketee K, Trapman J, Brinkmann AO.
    Mol Endocrinol; 1998 Aug 09; 12(8):1172-83. PubMed ID: 9717843
    [Abstract] [Full Text] [Related]

  • 25. Beta-catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription.
    Song LN, Herrell R, Byers S, Shah S, Wilson EM, Gelmann EP.
    Mol Cell Biol; 2003 Mar 09; 23(5):1674-87. PubMed ID: 12588987
    [Abstract] [Full Text] [Related]

  • 26. GRIP1 mediates the interaction between the amino- and carboxyl-termini of the androgen receptor.
    Shen HC, Buchanan G, Butler LM, Prescott J, Henderson M, Tilley WD, Coetzee GA.
    Biol Chem; 2005 Jan 09; 386(1):69-74. PubMed ID: 15843149
    [Abstract] [Full Text] [Related]

  • 27. An androgen receptor mutation in the direct vicinity of the proposed C-terminal alpha-helix of the ligand binding domain containing the AF-2 transcriptional activating function core is associated with complete androgen insensitivity.
    Peters I, Weidemann W, Romalo G, Knorr D, Schweikert HU, Spindler KD.
    Mol Cell Endocrinol; 1999 Feb 25; 148(1-2):47-53. PubMed ID: 10221770
    [Abstract] [Full Text] [Related]

  • 28. Androgen receptor mutations causing human androgen insensitivity syndromes show a key role of residue M807 in Helix 8-Helix 10 interactions and in receptor ligand-binding domain stability.
    Ong YC, Kolatkar PR, Yong EL.
    Mol Hum Reprod; 2002 Feb 25; 8(2):101-8. PubMed ID: 11818512
    [Abstract] [Full Text] [Related]

  • 29. Discordant measures of androgen-binding kinetics in two mutant androgen receptors causing mild or partial androgen insensitivity, respectively.
    Shkolny DL, Beitel LK, Ginsberg J, Pekeles G, Arbour L, Pinsky L, Trifiro MA.
    J Clin Endocrinol Metab; 1999 Feb 25; 84(2):805-10. PubMed ID: 10022458
    [Abstract] [Full Text] [Related]

  • 30. The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription.
    Alen P, Claessens F, Verhoeven G, Rombauts W, Peeters B.
    Mol Cell Biol; 1999 Sep 25; 19(9):6085-97. PubMed ID: 10454556
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Response to treatment in patients with partial androgen insensitivity due to mutations in the DNA-binding domain of the androgen receptor.
    Lundberg Giwercman Y, Nikoshkov A, Lindsten K, Byström B, Pousette A, Knudtzon J, Alm J, Wedell A.
    Horm Res; 2000 Sep 25; 53(2):83-8. PubMed ID: 10971094
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Trafficking of androgen receptor mutants fused to green fluorescent protein: a new investigation of partial androgen insensitivity syndrome.
    Georget V, Térouanne B, Lumbroso S, Nicolas JC, Sultan C.
    J Clin Endocrinol Metab; 1998 Oct 25; 83(10):3597-603. PubMed ID: 9768671
    [Abstract] [Full Text] [Related]

  • 36. A point mutation in the second zinc finger of the DNA-binding domain of the androgen receptor gene causes complete androgen insensitivity in two siblings with receptor-positive androgen resistance.
    Mowszowicz I, Lee HJ, Chen HT, Mestayer C, Portois MC, Cabrol S, Mauvais-Jarvis P, Chang C.
    Mol Endocrinol; 1993 Jul 25; 7(7):861-9. PubMed ID: 8413310
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. A naturally occurring mutation in the human androgen receptor of a subject with complete androgen insensitivity confers binding and transactivation by estradiol.
    Bonagura TW, Deng M, Brown TR.
    Mol Cell Endocrinol; 2007 Jan 15; 263(1-2):79-89. PubMed ID: 17011702
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.